Abstract:Abstract Background The identification of indeterminate pulmonary nodules (IPNs) following a low-dose computed tomography (LDCT) is a major challenge for early diagnosis of lung cancer. The inadequate assessment of IPNs’ malignancy risk results in a large number of unnecessary surgeries or an increased risk of cancer metastases. However, limited studies on non-invasive diagnosis of IPNs have been reported. Methods In this study, we identified and evaluated the diagnostic value of circulating small extracellular vesicle (sEV) microRNAs (miRNAs) in patients with IPNs that had been newly detected using LDCT scanning and were scheduled for surgery. Out of 459 recruited patients, 109 eligible patients with IPNs were enrolled in the training cohort (n = 47) and the test cohort (n = 62). An external cohort (n = 99) was used for validation. MiRNAs were extracted from plasma sEVs, and assessed using Small RNA sequencing. 490 lung adenocarcinoma samples and follow-up data were used to investigate the role of miRNAs in overall survival. Results A circulating sEV miRNA (CirsEV-miR) model was constructed from five differentially expressed miRNAs (DEMs), showing 0.920 AUC in the training cohort (n = 47), and further identified in the test cohort (n = 62) and in an external validation cohort (n = 99). Among five DEMs of the CirsEV-miR model, miR-101-3p and miR-150-5p were significantly associated with better overall survival (p = 0.0001 and p = 0.0069). The CirsEV-miR scores were calculated, which significantly correlated with IPNs diameters (p < 0.05), and were able to discriminate between benign and malignant PNs (diameter ≤ 1 cm). The expression patterns of sEV miRNAs in the benign, adenocarcinoma in situ/minimally invasive adenocarcinoma, and invasive adenocarcinoma subgroups were found to gradually change with the increase in aggressiveness for the first time. Among all DEMs of the three subgroups, five miRNAs (miR-30c-5p, miR-30e-5p, miR-500a-3p, miR-125a-5p, and miR-99a-5p) were also significantly associated with overall survival of lung adenocarcinoma patients. Conclusions Our results indicate that the CirsEV-miR model could help distinguish between benign and malignant PNs, providing insights into the feasibility of circulating sEV miRNAs in diagnostic biomarker development. Trial registration : Chinese Clinical Trials: ChiCTR1800019877. Registered 05 December 2018, https://www.chictr.org.cn/showproj.aspx?proj=31346 . Graphical Abstract

Serum Micrornas Improving the Diagnostic Accuracy in Lung Cancer Presenting with Pulmonary Nodules.

Seven-Microrna Panel For Lung Adenocarcinoma Early Diagnosis In Patients Presenting With Ground-Glass Nodules

Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers

The Role of Plasma Mirnas in the Diagnosis of Pulmonary Nodules

Circulating MicroRNA Panel As a Diagnostic Marker for Hepatocellular Carcinoma

Serum Microrna Signature Is Capable Of Early Diagnosis For Non-Small Cell Lung Cancer

Combination of Plasma Micrornas with Serum Ca19-9 for Early Detection of Pancreatic Cancer

Early Detection of Lung Cancer in Serum by a Panel of MicroRNA Biomarkers.

Combining Plasma Mirnas And Computed Tomography Features To Differentiate The Nature Of Pulmonary Nodules

Validation of a Serum 4-Microrna Signature for the Detection of Lung Cancer

Identification of Mirnas As Non-Invasive Biomarkers for Early Diagnosis of Lung Cancers

Circulating Micrornas As Specific Biomarkers for Breast Cancer Detection

A novel microRNA miR-4433a-3p as a potential diagnostic biomarker for lung adenocarcinoma

Early Detection of Non-Small Cell Lung Cancer by Using a 12-Microrna Panel and a Nomogram for Assistant Diagnosis

Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma.

The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers.

Identification and evaluation of circulating small extracellular vesicle microRNAs as diagnostic biomarkers for patients with indeterminate pulmonary nodules

OP0016 Development of a panel of five miRNAs as a diagnostic tool for non-small-cell lung cancer

Serum microRNA expression profiling revealing potential diagnostic biomarkers for lung adenocarcinoma

CLINICAL EVALUATION OF A PANEL OF CIRCULATING MICRORNAS IN NONSMALL CELL LUNG CANCER

Circulating miRNAs in Serum as Biomarkers for Early Diagnosis of Non-small Cell Lung Cancer